Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells (HSP70CTC)

Charité University Medicine Berlin

Status: Unknown

Conditions: Breast Cancer Stage IV; Squamous Cell Carcinoma; Sarcoma; Melanoma Stage IV; Pancreatic Cancer Stage IV; Prostate Cancer

Treatments: Diagnostic Test: CTC isolation by HSP70

Study type: Observational

Funder types: Other

Identifiers

NCT04628806

HSP70CTC

Details and patient eligibility

About

This study investigates the ability of heat shock protein HSP70 to isolate and quantify circulating tumor cells (CTCs) in patients with advanced or metastatic tumors.

CTCs will be isolated from peripheral blood before antineoplastic treatment and again after three months. Isolation using HSP70 will be compared with standard CTC isolation by EpCAM.

Additionally, imaging parameters of the primary tumor (if available) and metastases will be analysed and correlations between molecular alterations and imaging parameters will be assesed.

Enrollment: 120 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Metastatic malignant melanoma (stage IV)
• Metastatic or unresectable pancreatic adenocarcinoma (stage III or IV)
• Metastatic breast cancer
• Metastatic sarcoma
• Metastatic squamous cell carcinoma of the cervix uteri, head and neck region, vulva, anus or penis
• hormone-refractory prostate cancer

Exclusion criteria

• psychiatric disorders that impede adequate informed consent

Trial design

120 participants in 1 patient group

HSP70CTC

Description:

Isolation of circulating tumor cells by HSP70

Treatment:

Diagnostic Test: CTC isolation by HSP70